339308-60-0

339308-60-0 structure

Name: Briakinumab
Chemical Name: Briakinumab
CAS Number: 339308-60-0
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2023-03-09 21:33:23
Modify Date: 2024-04-09 14:27:31
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis[1].

Name	Briakinumab

Description	Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
Target	IL-12 IL-23
In Vitro	Briakinumab targets the p40 molecule shared by interleukin-12 and interleukin-23[2].
References	[1]. Panaccione R, et, al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. [2]. Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586-96.

No Any Chemical & Physical Properties